Hiroaki Kanemura

🔥Reimagining HER2 Tx: bridging oncogene addiction and immune modulation 🆙 @Cancer_Cell ☑HER2 suppresses antigen presentation & enhances checkpoint expression 🎙Dr. Luke Tillman @sundar__raghav @OncoAlert @Larvol cell.com/cancer-cell/ab…

Excited to see the full presentation #ASCO26 by @LaurenByersMD on ABBV-706, a SEZ6 ADC with promising activity in relapsed/refractory #SCLC! 📊 Key results: • ORR 82% in 2L pts (1.8 mg/kg) ‼️ • mOS 14.3 mo in 2L monotherapy • 15-mo OS rate: 50% • Combo w/ budigalimab (anti-PD-1): ORR 55%, mPFS 8.1 mo, no new safety signals ⭐️No treatment-related deaths. No pneumonitis with combo! (small n) An ADC target in SCLC worth watching !! 👀 @drshieldsmd @ASCO #lcsm @alissajcooper

Unlocking the potential of T cell engagers in solid tumors dlvr.it/TSc3Xc

Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC - Bruna Pellini @BrunaPellini @hilalozakinci @Binadesai14 @AndriyMarusyk oncodaily.com/voices/bruna-p…

🫁 AACR Lung Cancer Roadmap. AACR outlines key priorities to further reduce lung cancer mortality despite major advances in targeted therapy, immunotherapy, and screening. Key focus areas: • Prevention and interception • Earlier detection • Precision oncology and biomarkers • Resistance mechanisms • AI-driven analytics and innovative trial designs • Reducing disparities and neglected subtypes A strategic framework for the next era of thoracic oncology research and care. 📖 @CD_AACR DOI 👉🏻 doi.org/10.1158/2159-8… #CánCare #lcsm #ThoracicOncology #NSCLC #SCLC #PrecisionOncology

Massive amount of updates in KRAS at #RomeLung26 from Dr. @FSkoulidis - two G12C inhibitors approved, next gen agents overcoming resistance, potential role earlier with front line combinations. Excitement for early stage role. And recent gains in G12D and pan-(K)RAS inhibitors.

Daraxonrasib in PDAC now published in NEJM. We have had press releases and presentations, but now a publication. And yes, the data still look very real. 🧬 Pancreatic cancer is a RAS disease. 90% have activating RAS mutations. G12D, G12V, G12R dominate. And historically we have had essentially nothing direct to do about it (G12C inhibitors exist but they are a subpopulation). Phase 1/2 Previously treated RAS-mutant PDAC n=168 Oral RAS(ON) multi-selective inhibitor Phase 3 dose: 300 mg daily • ORR 35% • mDoR 8.2 months • mPFS 8.5 months • mOS 13.1 months As context; 2L chemo w/ PDAC has ORR <10% with OS ~5-7 months and significant side effects. So yes, this is huge. Toxicity is real too: • Any-grade TRAE 96% • Grade ≥3 TRAE 30% • Rash, diarrhea, nausea, mucositis, vomiting, fatigue This is not a “write the script and see them in a month” drug. Up-front oncoderm involvement is going to be critical. Rash needs to be anticipated, managed early, and dose modifications need to be normalized rather than viewed as failure. BUT this is a absolute game-changer in pancreas cancer (and other KRAS driven diseases). Importantly, this no longer exists in a phase 1/2 vacuum. By press release, RASolute 302 met its primary and key secondary endpoints, with PFS and OS benefit versus standard chemotherapy. Full data still matter, but the confirmatory study appears to have confirmed the signal. Terrible disease. Great signal. Real (but manageable) toxicity. Practice-changing. nejm.org/doi/full/10.10… @OncoAlert @TheGutOncLab @Onco_Nexus

The Godfather of RAS! @KRASKickers

🫁 Metastatic trajectories in NSCLC. Lesion-level dynamics may better define metastatic NSCLC than static oligometastatic classifications. Integrating ctDNA, radiomics, organotropism, and progression patterns could refine patient selection for local and systemic therapies and support adaptive treatment strategies. 📖 JCO doi.org/10.1200/JCO-25… #CánCare #NSCLC #lcsm #thoraciconcology #biomarkers

ASCOは毎年クソデカ演題が出て標準治療をひっくり返すような発表が目白押しだが、今年はまたすごそうだな。特に膵癌で本格的にRAS阻害薬が既存の化学療法をフルボッコにし始めたのがすごい… #ASCO26

00m.in/qBfXw Our review article on perioperative immunotherapy has just been published in the new English-language journal of the Japan Lung Cancer Society I would very much welcome your comments, criticisms, and discussion.

#KRAS remains one of the most dynamic areas in #lungcancer research. What stood out at #AACR2026? @StephenVLiu is joined by @DDoroshow, @DavidHongMD, and Dr. Jonathan Riess to break down the latest updates, and what they mean for clinical practice. 🎧 bit.ly/4nrxDu9 #LungCancerConsidered #ThoracicOncology

論文抄読会のためのスライド作成をNotebookLM→ChatGPTで95%自動化する方法🔥 この方法なら - 論文の図表をそのままスライドに挿入 - "AIっぽさ"を徹底排除したシンプルデザイン - pptxファイルで手直しも自由。 - 準備するのは論文PDFと図表のスクショのみ 詳細な手順はリプ欄で解説します👇

Nature投書。研究現場におけるAIエージェント：生産性の向上が見習いの機会を奪うとき 「Claude Code」と「OpenClaw」を幅広く活用するようになり、院生を仕事にかかわらせなくなってきた。AIの活用と、学生の成長に不可欠な実践的な研究体験を守る必要性とのバランスが重要。 nature.com/articles/d4158…

Resistance mechanisms to RAS(ON) tri-complex inhibitor daraxonrasib ◾️KRAS Y64 mutations: Disrupt drug's binding to RAS ◾️KRAS Y71 mutations: Enhance RAS affinity for RAF, competing with CYPA recruitment ◾️Class III BRAF mutations: Promote RAF dimerization, strengthening RAS-RAF engagement 👉Next steps: Next-generation TCI (RMC-4791) to overcome Y64 resistance, or combination with RAF dimer-breakers for class III BRAF 🔗doi.org/10.1016/j.cell… @CellCellPress @OncoAlert @RonaYaeger

While the me2 companies are still planning on Ph2 dose optimizations, $RVMD had already worked out the comprehensive real-world acquire resistance mechanisms for Darax. One of the most elegant cell signaling papers that I had ever seen I read their prior Biorxiv and never quite understood how BRAF kinase dead mutants confer resistance to Darax. Now they had provided a very clear answer Glad to see all these genius-level people there (including all the investigators on the paper)! cell.com/cell/fulltext/…

🫁 Lung cancer is no longer just about treating disease, it’s about intercepting its evolution! aacrjournals.org/cancerdiscover… This AACR roadmap lays out the shift: ▪️ From late-stage care → early detection & prevention ▪️ From static biology → dynamic tumor evolution ▪️ From single targets → multi-omic integration ▪️ From relapse treatment → MRD-driven intervention The future? Anticipate. Intercept. Adapt. @OncoAlert @OncoReporte @myESMO @_SEOM @LungCancerRx @Lung_Cancers

Really thoughtful review from @raffcolo et al. in @Annals_Oncology challenging the ADC assumption: “more stable linker = better ADC.” The clinical story is nuanced. Some successful ADCs are relatively unstable, while more stable designs can shift toxicity rather than solve it. For example, ocular toxicity with stable auristatin ADCs being a striking example. And the humbling reminder: often <1% of an injected antibody/ADC dose reaches tumor. Maybe the goal isn’t maximum linker stability, but the right instability in the right biological context. annalsofoncology.org/article/S0923-…

若手研究者向け研究費申請支援GPT (G-DPA) を一般公開しました🎉 2か月前に春の自由研究として開発を始め、ようやく皆様にお届けできるようになりました。Note末尾の「注意事項」「お願い」をご確認・同意の上、ぜひご活用ください！ 少しでもお役に立てれば幸いです。 note.com/mishizaka/n/nd…

学生さんから学振のチェックをお願いされた。 DC学振は三振してもう一生消えないコンプレックスだから、そうならないようにできることは手伝いたいところ。 筆頭論文や受賞歴があってもDC学振三振したことをまとめた記事を載せておこう。 note.com/imawish1126/n/…